1. Home
  2. TOP vs VERU Comparison

TOP vs VERU Comparison

Compare TOP & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

HOLD

Current Price

$1.05

Market Cap

43.0M

Sector

Finance

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.56

Market Cap

41.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
VERU
Founded
2015
1971
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
41.7M
IPO Year
2022
1990

Fundamental Metrics

Financial Performance
Metric
TOP
VERU
Price
$1.05
$2.56
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
51.6K
128.5K
Earning Date
01-20-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,355,086.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
59.48
N/A
52 Week Low
$0.94
$2.10
52 Week High
$3.33
$7.40

Technical Indicators

Market Signals
Indicator
TOP
VERU
Relative Strength Index (RSI) 51.47 51.24
Support Level $0.95 $2.46
Resistance Level $1.08 $2.84
Average True Range (ATR) 0.05 0.20
MACD 0.00 0.01
Stochastic Oscillator 50.00 53.12

Price Performance

Historical Comparison
TOP
VERU

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: